Lantheus Holdings, Inc.
LNTH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LNTH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LNTH
Lantheus Holdings is a radiopharmaceutical-focused company that develops, manufactures, and commercializes products for oncology and precision diagnostics, with approved products including PYLARIFY, DEFINITY, and Neuraceq, and a pipeline of investigational candidates.
Key risk: Integration of acquisitions
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 9 pipeline candidates · 4 clinical trials · 3 catalysts for Lantheus Holdings, Inc..
Lantheus Holdings is a radiopharmaceutical-focused company that develops, manufactures, and commercializes products for oncology and precision diagnostics, with approved products including PYLARIFY, DEFINITY, and Neuraceq, and a pipeline of investigational candidates.
- Cash & equivalents of $595.0M, total revenue of $388.2M, net income of $75.0M, shareholders' equity of $1,166.8M, and total debt of $571.1M as of 2026-06-30 [sec].
- Products impacted nearly seven million patients and their families in 2025 [sec · filed 2026-03-20].
- Filed INDs for LNTH-2403 (osteosarcoma) and LNTH-2401/2402 (prostate cancer), and submitted an NDA for MK-6240 [sec · filed 2026-03-20].
- Completed CMC development and Phase 3 trial for NAV-4694, though rated 'Below Expectations' [sec · filed 2026-03-20].
- Executed strategic transactions including acquisition of Meilleur Technologies Inc. (NAV-4694) and in-licensing of TROP2, LRRC15, and RM2 [sec · filed 2025-03-21].
What works
- Lantheus is the leading radiopharmaceutical-focused company with a portfolio spanning oncology, precision diagnostics, and strategic partnerships [sec_mda · as of 2026-02-26].
- The company has a diversified product base including PYLARIFY, DEFINITY, and Neuraceq, and is expanding through in-licensing and acquisitions [sec_mda · as of 2026-02-26].
- Lantheus has a strong cash position of $595.0M as of 2026-06-30, providing financial flexibility for R&D and potential acquisitions [sec].
What to weigh
- The company faces competition and pricing pressure in its marketed products, particularly PYLARIFY, DEFINITY, and Neuraceq [sec_mda · as of 2026-02-26].
- Integration risks from acquisitions (Lantheus Biosciences Ltd., Evergreen Theragnostics, Inc.) could lead to unforeseen expenses and liabilities [sec · filed 2026-08-04].
- The NAV-4694 program was rated 'Below Expectations' in 2025, indicating development challenges [sec · filed 2026-03-20].
- Lantheus has $571.1M in total debt as of 2026-06-30, which may constrain financial flexibility [sec].
From the filings
Quoted directly from source documents.
Lantheus is the leading radiopharmaceutical-focused company
“We are the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to”
SEC filings · March 21, 2025
Filed IND for LNTH-2403 and LNTH-2401/2402
“Filed investigational new drug ("IND") application for LNTH-2403 for osteosarcoma”
SEC filings · March 20, 2026
Integration risks from acquisitions
“the Company's ability to continue to successfully integrate acquisitions, including of Lantheus Biosciences Ltd. (formerly Life Molecular Imaging Limited) and Evergreen Theragnostics, Inc., which could be impacted by unforeseen expenses related to integration activities”
SEC filings · August 4, 2026
Catalyst timeline
- 2031-03-10 · Patent_Expiry · RELISTOR — Patent/exclusivity expiry for RELISTOR could open the market to generic competition, potentially impacting revenue.
- 2037-05-04 · Patent_Expiry · DEFINITY — Patent/exclusivity expiry for DEFINITY may allow generic entrants, affecting Lantheus's market share.
- 2037-06-09 · Patent_Expiry · PYLARIFY — Patent/exclusivity expiry for PYLARIFY could lead to competition and revenue decline for this key product.
Risks & what to watch (4)›
Key risks
- Integration of acquisitions — Unforeseen expenses, liabilities, and challenges in integrating IT systems and talent from Lantheus Biosciences Ltd. and Evergreen Theragnostics [sec · filed 2026-08-04].
- Competition and pricing pressure — Revenue mix shifts and volume/price changes from additional competition or changes in customer demand for PYLARIFY, DEFINITY, and Neuraceq [sec_mda · as of 2026-02-26].
- Debt obligations — Total debt of $571.1M as of 2026-06-30 may limit financial flexibility and require significant cash outflows for servicing [sec].
- Pipeline development setbacks — NAV-4694 program rated 'Below Expectations' in 2025, indicating potential delays or failures in clinical development [sec · filed 2026-03-20].
What to watch
- FDA approval decision for LNTH-2501, an investigational kit for Gallium-68 edotreotide injection [sec · filed 2026-08-04].
- Progress of the NDA for MK-6240 and Phase 3 trial for NAV-4694 [sec · filed 2026-03-20].
- CEO search and leadership transition, as the Executive Chairperson is serving as Interim CEO [sec · filed 2026-03-20].
- Patent expiries for RELISTOR (2031-03-10), DEFINITY (2037-05-04), and PYLARIFY (2037-06-09) [upcoming catalysts].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Lantheus Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lantheus Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.84 · 4% dilution
Lead: Approved
9 candidates
3 upcoming, next in ~1653d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
403
Total value held
$5.91B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 9,549,682 | $724.3M |
| blackrock, inc. | 8,183,193 | $620.7M |
| vanguard capital management llc | 5,828,628 | $442.1M |
| farallon capital management llc | 5,583,479 | $423.5M |
| fmr llc | 4,626,453 | $350.9M |
| vanguard portfolio management llc | 3,174,274 | $240.8M |
| state street corp | 2,429,803 | $184.3M |
| american century companies inc | 1,781,106 | $135.1M |
| geode capital management, llc | 1,765,952 | $134.0M |
| morgan stanley | 1,646,463 | $124.9M |
Showing top 10 of 403 institutional holders of Lantheus Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 10.9%
- Days to cover
- 4.6
- Shares short
- 5,356,878
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LNTH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lantheus Holdings, Inc.?
Lantheus Holdings is a radiopharmaceutical-focused company that develops, manufactures, and commercializes products for oncology and precision diagnostics, with approved products including PYLARIFY, DEFINITY, and Neuraceq, and a pipeline of investigational candidates.
What is Lantheus Holdings, Inc.'s lead drug candidate?
Lantheus Holdings, Inc.'s most advanced tracked candidate is DEFINITY (Approved) for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve delineation of the left ventricular endocardial border.
What is Lantheus Holdings, Inc.'s next catalyst?
Lantheus Holdings, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: RELISTOR" — expected March 10, 2031.
Who is the CEO of Lantheus Holdings, Inc.?
Ms. Mary Anne Heino is the chief executive officer of Lantheus Holdings, Inc. (LNTH).
Where is Lantheus Holdings, Inc. headquartered?
Lantheus Holdings, Inc. (LNTH) is headquartered in Bedford, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.